Skip to main content
. Author manuscript; available in PMC: 2021 Sep 11.
Published in final edited form as: Circ Res. 2020 Jun 29;127(7):855–873. doi: 10.1161/CIRCRESAHA.120.316951

Figure 1. Kawasaki disease (KD) platelets exhibit differential expression of miR-223 dependent on the severity of coronary pathology.

Figure 1.

(A) Heatmap of differentially expressed miRNAs in platelets from healthy control (HC) (n=3), KD patients in non-coronary arterial aneurysm (NCAA) group (n=5) and coronary arterial aneurysm (CAA) group (n=3). (B) CAA patients were divided into three groups, small CAA (SCAA), medium CAA (MCAA), giant CAA (GCAA), according to coronary artery Z-worst. Representative echocardiogram images of corresponding patients with SCAA, MCAA, GCAA or NCAA, were shown. (C) Levels of miR-223 in platelets from HC (n=29), KD patients in NCAA group (n=88) and CAA group (n=28) were determined by droplet digital PCR (ddPCR) and presented as copies per microliter (μl) in each sample (Kruskall-Wallis test and Dunn’s multiple comparisons test). (D) Levels of miR-223 in platelets from each group (SCAA: n=12, MCAA: n=7, GCAA: n=9) were measured by ddPCR (Kruskall-Wallis test and Dunn’s multiple comparisons test). Binary logistic regression analysis was performed, and ROC values were generated to evaluate the ability of platelet miR-223 to distinguish, (E) HC from KD patients with CAA and NCAA, (F) KD patients in NCAA group from CAA group, (G) KD patients with SCAA and MCAA from GCAA. *P<0.05, ***P<0.001, ****P<0.0001.